Stockscreener 앱 받기
1.97
2.07%
0.04
Pacific Biosciences Of California Inc 주식(PACB)의 최신 뉴스
Reasons to Retain PacBio Stock in Your Portfolio for Now - MSN
Fmr LLC Has $694,000 Holdings in Pacific Biosciences of California, Inc. (NASDAQ:PACB) - MarketBeat
Pacific Biosciences updates executive severance agreements By Investing.com - Investing.com Canada
Pacific Biosciences updates executive severance agreements - Investing.com India
Pacific Biosciences Updates Executive Severance Agreements - TipRanks
Pacific Biosciences of California, Inc. announced that it expects to receive $50 million in funding - Marketscreener.com
Long Read Sequencing Market Industry Dynamics - openPR
Why Pacific Biosciences of California (PACB) Is the Worst ARK Stock to Buy According to Short Sellers - Insider Monkey
BNP Paribas Financial Markets Reduces Holdings in Pacific Biosciences of California, Inc. (NASDAQ:PACB) - MarketBeat
10 Worst ARK Stocks To Buy According to Short Sellers - Insider Monkey
Pacific Biosciences names CEO as interim CFO By Investing.com - Investing.com Australia
Pacific Biosciences of California (NASDAQ:PACB) Shares Gap UpHere's Why - MarketBeat
Pacific Biosciences names CEO as interim CFO - Investing.com
Soros Fund Management LLC Grows Position in Pacific Biosciences of California, Inc. (NASDAQ:PACB) - MarketBeat
PACB (Pacific Biosciences of California) Net Issuance of Pr - GuruFocus.com
Cathie Wood's Ark Invest Bets Big On Biotech Again As Pacific Biosciences Grabs Spotlight - Benzinga
Pacific Biosciences of California, Inc. (NASDAQ:PACB) Receives Average Rating of "Hold" from Analysts - MarketBeat
PacBio Reports Equity Incentive Awards to New Employees Under Na - GuruFocus.com
Pacific Biosciences of California (NASDAQ:PACB) Trading 7.4% HigherShould You Buy? - MarketBeat
Shrimp Hydrolysate Market Set to Surge to $675.9 Million with an Impressive 8.7% CAGR by 2034 - GlobeNewswire Inc.
SOFTBANK GROUP CORP. Acquires Significant Stake in Pacific Biosciences of California Inc - GuruFocus.com
PACB (Pacific Biosciences of California) 3-Year Revenue Gro - GuruFocus.com
PacBio to Report Third Quarter 2024 Financial Results on November 7, 2024 - Quantisnow
Senvest Management LLC Boosts Stock Position in Pacific Biosciences of California, Inc. (NASDAQ:PACB) - MarketBeat
PACB Stock Falls Despite Q3 Earnings Beat, Revenues Decline Y/Y - MSN
Pacific Biosciences of California, Inc. (PACB): Among the Best Genomics Stocks to Buy Right Now - Yahoo Finance
10 Best Genomics Stocks To Buy Right Now - Insider Monkey
Sumitomo Mitsui Trust Group Inc. Has $20.17 Million Stake in Pacific Biosciences of California, Inc. (NASDAQ:PACB) - MarketBeat
Research Analysts Offer Predictions for PACB FY2024 Earnings - MarketBeat
DNA Sequencing Market to Grow by USD 17.34 Billion (2024-2028), Driven by Rising NGS Adoption, AI-Powered Report Explores Market EvolutionTechnavio - The Malaysian Reserve
Pacific Biosciences of California (NASDAQ:PACB) Upgraded by UBS Group to "Hold" Rating - MarketBeat
Pacific Biosciences CCO departs amid restructuring By Investing.com - Investing.com Australia
Pacific Biosciences CCO departs amid restructuring - Investing.com India
Pacific Biosciences' Cost Cuts Won't Offset Rising Competition (NASDAQ:PACB) - Seeking Alpha
Pacific Biosciences of California Inc (PACB) Quarterly 10-Q Report - Quartzy
Pacific Biosciences of California (NASDAQ:PACB) Trading Up 5.3% Following Analyst Upgrade - MarketBeat
Pacific Biosciences of California, Inc. Announces Resignation of Susan Kim as Chief Financial Officer, Effective December 6, 2024 - Marketscreener.com
Pacific Biosciences of California Third Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag - Yahoo Finance
UBS Downgrades Pacific Biosciences of California (PACB) - MSN
Pacific Biosciences of California (PACB) Reports Q3 Loss, Misses Revenue Estimates - MSN
Cathie Wood's ARK sells Unity, buys Pacific Biosciences stock By Investing.com - Investing.com Nigeria
Cathie Wood's ARK sells Unity, buys Pacific Biosciences stock - Investing.com
PacBio’s $459 Million Convertible Note Exchange Offering - Global Legal Chronicle
Scotiabank Lowers Pacific Biosciences of California (NASDAQ:PACB) Price Target to $6.00 - MarketBeat
1.54%
자본화:
|
볼륨(24시간):